Literature DB >> 8001648

Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats.

M W Decker1, P Curzon, J D Brioni, S P Arnerić.   

Abstract

Septal lesions disrupt septohippocampal neurotransmission and impair spatial memory. (-)-Nicotine reduces the memory deficits but has substantial side effect liabilities. Previous studies have demonstrated that ABT-418 is a novel, selective ligand for neuronal nicotinic acetylcholine receptors. In the current study, ABT-418 (0.19 and 1.9 mumol/kg, i.p.) administered before training significantly attenuated lesion-induced deficits in a spatial discrimination version of the Morris water maze. As lesion-induced learning deficits might parallel the cognitive deficits characteristic of Alzheimer's disease, these results suggest that ABT-418 may be useful in the treatment of this condition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8001648     DOI: 10.1016/0014-2999(94)90323-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Increased neurodegeneration during ageing in mice lacking high-affinity nicotine receptors.

Authors:  M Zoli; M R Picciotto; R Ferrari; D Cocchi; J P Changeux
Journal:  EMBO J       Date:  1999-03-01       Impact factor: 11.598

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Drug enhancement of memory consolidation: historical perspective and neurobiological implications.

Authors:  James L McGaugh; Benno Roozendaal
Journal:  Psychopharmacology (Berl)       Date:  2008-08-15       Impact factor: 4.530

4.  H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization.

Authors:  Victoria A Komater; Kaitlin E Browman; Peter Curzon; Arthur A Hancock; Michael W Decker; Gerard B Fox
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

Review 5.  Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

Authors:  P A Newhouse; A Potter; E D Levin
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

6.  The scopolamine model as a pharmacodynamic marker in early drug development.

Authors:  Robert A Lenz; Jeffrey D Baker; Charles Locke; Lynne E Rueter; Eric G Mohler; Keith Wesnes; Walid Abi-Saab; Mario D Saltarelli
Journal:  Psychopharmacology (Berl)       Date:  2011-09-08       Impact factor: 4.530

7.  Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clamp study.

Authors:  B Buisson; M Gopalakrishnan; S P Arneric; J P Sullivan; D Bertrand
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

Review 8.  Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms.

Authors:  G Mudo; N Belluardo; K Fuxe
Journal:  J Neural Transm (Vienna)       Date:  2006-08-17       Impact factor: 3.575

Review 9.  Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings.

Authors:  Susanne Graef; Peter Schönknecht; Osama Sabri; Ulrich Hegerl
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

10.  Nicotinic agonist-induced improvement of vigilance in mice in the 5-choice continuous performance test.

Authors:  Jared W Young; Jessica M Meves; Mark A Geyer
Journal:  Behav Brain Res       Date:  2012-11-29       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.